Leading ALS authority Merit Cudkowicz joins TikoMed’s newly formed Scientific Advisory Board
Viken – September 19, 2023 – Today, Swedish biopharmaceutical company TikoMed AB announced the formation of its Scientific Advisory Board (SAB).The SAB will work cohesively with management to advance the company’s clinical development of ILB, TikoMeds drug in Phase 2 development in ALS. The board will integrate highly experienced clinicians as well as seasoned industrial scientific leaders in the field. The first member to be announced is Dr. Merit Cudkowicz. Dr. Merit Cudkowicz is the Director of the Sean M. Healey & AMG Center for ALS, Chair of Neurology at Mass General, and the